Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce W Bode

Showing results (31-40 of 128) with videos related to

Pageof 13
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2009
Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratioPaul C Davidson, Harry R Hebblewhite, Robert D Steed, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapyBruce W Bode, Susan S Braithwaite, R Dennis Steed, et al.
Journal of Diabetes Science and Technology|November 4, 2009
A cause-and-effect-based mathematical curvilinear model that predicts the effects of self-monitoring of blood glucose frequency on hemoglobin A1c and is suitable for statistical correlationsPaul C Davidson, Bruce W Bode, R Dennis Steed, et al.
Diabetes Technology & Therapeutics|July 15, 2015
The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring SystemTimothy Bailey, Bruce W Bode, Mark P Christiansen, et al.
Diabetes Technology & Therapeutics|January 6, 2017
Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin InfusionBruce W Bode, Joseph A Johnson, Liselotte Hyveled, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 7, 2023
Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in RangeTimothy S Bailey, Bruce W Bode, Qianqian Wang, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Advances in hemoglobin A1c point of care technologyBruce W Bode, Benjamin R Irvin, Jeffrey A Pierce, et al.
Diabetes Technology & Therapeutics|April 21, 2016
Response to the Comment on "The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System" by Bailey et alTimothy S Bailey, Shridhara Alva, Bruce W Bode, et al.
Diabetes Technology & Therapeutics|April 5, 2011
Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trialArianne C van Bon, Bruce W Bode, Caroline Sert-Langeron, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 30, 2015
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALSDaniel Einhorn, Yehuda Handelsman, Bruce W Bode, et al.
Pageof 13

Showing results (31-40 of 128) with videos related to

Sort By:
Pageof 13
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2009
Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratioPaul C Davidson, Harry R Hebblewhite, Robert D Steed, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapyBruce W Bode, Susan S Braithwaite, R Dennis Steed, et al.
Journal of Diabetes Science and Technology|November 4, 2009
A cause-and-effect-based mathematical curvilinear model that predicts the effects of self-monitoring of blood glucose frequency on hemoglobin A1c and is suitable for statistical correlationsPaul C Davidson, Bruce W Bode, R Dennis Steed, et al.
Diabetes Technology & Therapeutics|July 15, 2015
The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring SystemTimothy Bailey, Bruce W Bode, Mark P Christiansen, et al.
Diabetes Technology & Therapeutics|January 6, 2017
Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin InfusionBruce W Bode, Joseph A Johnson, Liselotte Hyveled, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 7, 2023
Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in RangeTimothy S Bailey, Bruce W Bode, Qianqian Wang, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Advances in hemoglobin A1c point of care technologyBruce W Bode, Benjamin R Irvin, Jeffrey A Pierce, et al.
Diabetes Technology & Therapeutics|April 21, 2016
Response to the Comment on "The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System" by Bailey et alTimothy S Bailey, Shridhara Alva, Bruce W Bode, et al.
Diabetes Technology & Therapeutics|April 5, 2011
Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trialArianne C van Bon, Bruce W Bode, Caroline Sert-Langeron, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 30, 2015
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALSDaniel Einhorn, Yehuda Handelsman, Bruce W Bode, et al.
Pageof 13